Latest News

Latest News

• Aroa Biosurgery to list on the ASX in $225m IPO
• Aroa Biosurgery opens new pathway for advanced wound treatment amidst COVID-19 disruption in the United States
• COVID-19 Update – Aroa Biosurgery is well placed to maintain supply of Endoform® and Myriad™ products to clinicians and patients
• Aroa Biosurgery expands options for soft tissue repair with launch of Myriad™
• Aroa Biosurgery launches large format Endoform® to treat larger, more complex wounds
• Aroa Biosurgery appoints experienced Australian-based director
• Aroa Biosurgery appoints new Vice President, Commercial
• Aroa Biosurgery grows into additional markets with positive outcomes from Canadian clinical study
• Aroa Biosurgery posts maiden profit as it expands sales presence in U.S. and global markets
• TELA Bio begins commercialization for Large Size OviTex® Reinforced BioScaffolds for Hernia Repair and Abdominal Wall Reconstruction after Aroa Biosurgery receives 510k clearance.
• TELA Bio® Announces Initial Data from BRAVO Study of OviTex® Reinforced BioScaffolds for Ventral Hernia Repair
• TELA Bio® Announces Plans to Launch OviTex® Reinforced BioScaffolds in Europe
• Aroa Biosurgery and Hydrofera Team up in US
• FDA Clearance for Endoform® Silver Dermal Template
• Big investment in Aroa Biosurgery‘s Commercial Partner
• EC Certification for Endoform® Dermal Template
• 510(k) Clearance Received for Endoform® Plastics and Reconstructive Matrix
• Aroa Biosurgery successfully raises additional capital to fund growth
• Launch of Ovitex Reinforced Bioscaffolds
• Aroa Biosurgery wins NZBIO top award
• Aroa Biosurgery poised for global growth
• Aroa Corporate Update